The Cytel Blog: Perspectives on Enquiry & Evidence

Traditionally, clinical trials are expensive, long in duration, and have low success rate. But with the advent of rich..

New medicines and devices under development live and die on the strength of their clinical data. An asset’s journey is..

For over a decade, the number one reason cited for trial discontinuity has been challenges associated with recruitment..

The past two years have been transformative for Cytel. Most notably, the global COVID-19 pandemic unleashed an..

The aim of any clinical research is to detect the actual difference in treatment effect between two groups (power) and..

When choosing the optimal clinical trial design for a given study, sponsors face critical questions like choice of..

When Cyrus Mehta introduced the Promising Zone Design over a decade ago, the new statistical method not only..

Much of the discussion about clinical trial design considers methods to optimize performance characteristics and..

Next week’s PSI Conference will feature Dr. Yannis Jemiai speaking on the use of Scoring Functions in the re-imagined..